A cost-effectiveness analysis of stop smoking interventions in substance-use disorder populations

Nicotine and Tobacco Research

Volumn 21, Issue 5, 2019, Pages 623-630

  Healey, Andrew ^a   Roberts, Sarah ^a   Sevdalis, Nick ^a   Goulding, Lucy ^a   Wilson, Sophie ^a   Shaw, Kate ^a   Jolley, Caroline ^b,c   Robson, Deborah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG DEPENDENCE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; SOCIAL SUPPORT; TOBACCO DEPENDENCE; AGED; BEHAVIOR THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; ENGLAND; FEMALE; HEALTH PROMOTION; MIDDLE AGED; PROCEDURES; SMOKING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; ENGLAND; FEMALE; HEALTH PROMOTION; HUMANS; MALE; MIDDLE AGED; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS; TOBACCO SMOKING;

EID: 85063990240     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nty087     Document Type: Article

References (30)

1. Guydish J, Passalacqua E, Pagano A, et al. An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111(2):220-230.
2. West R, May S, West M, Croghan E, McEwen A. Performance of English stop smoking services in first 10 years: Analysis of service monitoring data. BMJ. 2013;347:f4921.
3. Stapleton JA, West R. A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: Application to a new cytisine trial and other examples. Nicotine Tob Res. 2012;14(4):463-471.
4. Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press; 2015.
5. NICE. Methods for the Development of NICE Public Health Guidance. 3rd ed. London, UK: National Institute for Health and Care Excellence; 2012.
6. West R, Owen L. Estimates of 52-weel Abstienence Rates Following Selected Smoking Cessation Interventions in England: Version 2. 2012.
7. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A. What makes for an effective stop-smoking service? Thorax. 2011;66(10):924-926.
8. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ. 2013;14(5):789-797.
9. Stapleton JA, Keaney F, Sutherland G. Illicit drug use as a predictor of smoking cessation treatment outcome. Nicotine Tob Res. 2009;11(6):685-689.
10. Richter KP, Ahluwalia HK, Mosier MC, Nazir N, Ahluwalia JS. A population-based study of cigarette smoking among illicit drug users in the United States. Addiction. 2002;97(7):861-869.
11. EMCCDA. Mortality Among Drug Users in Europe: New and Old Challenges for Public Health. Luxembourg: Publications Office of the European Union; 2015.
12. NICE. Judging Whether Public Health Interventions Offer Value for Money. London, UK: National Institute for Health and Care Excellence; 2013.
13. NDTMS. Adult Substance Misuse Statistics from the National Drug Treatment Monitoring System (NDTMS). London, UK: 1st April 2015 to 31st March 2016. 2016.
14. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
15. Flack ST, Taylor M, Trueman, P. Cost-effectiveness of Interventions for Smoking Cessation. York: University of York; 2007.
16. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: Implications for economic evaluations. BMC Public Health. 2012;12:203.
17. NHS. Health Survey for England 2006: Cardiovascular Disease and Risk Factors. 2008.
18. Brooks R. EuroQol: The current state of play. Health Policy. 1996;37(1):53-72.
19. NICE. Developing NICE Guidelines: The Manual. London, UK: National Institute for Health and Care Excellence; 2014.
20. Chang CK, Hayes RD, Broadbent M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: A cohort study. BMC Psychiatry. 2010;10:77.
21. ONS. Mortality statistics: Deaths registered in 2008. 2008. http:// webarchive.nationalarchives.gov.uk/20160108063958/http://www.ons. gov.uk/ons/rel/vsob1/mortality-statistics-deaths-registered-in-englandand-wales-series-dr-/2008/index.html. Accessed September 1, 2017.
22. Weinberger AH, Gbedemah M, Wall MM, Hasin DS, Zvolensky MJ, Goodwin RD. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: Emerging disparities in vulnerable populations. Addiction. 2018;113(4):719-728.
23. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233.
24. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851-859.
25. Davies L, Jones A, Vamvakas G, Dubourg R, Donmall M. The Drug Treatment Outcomes Research Study (DTORS): cost-effectiveness analysis. In: Home Office; 2009.
26. Jones AD, Millar M, Moody T, et al. The Drug Treatment Outcomes Research Study (DTORS): Final outcomes report. 2009.
27. Ferguson J, Bauld L, Chesterman J, Judge K. The English smoking treatment services: One-year outcomes. Addiction. 2005;100(Suppl 2):59-69.
28. (PSSRU) PSSRU. Units Costs of Health and Social Care 2016. 2016.
29. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1-503, v.
30. Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337(15):1052-1057.